UK medtech specialising in ophthalmology engaged Treehill.
The medtech had an ophthalmology asset with the ability to ameliorate the impact from damage caused by Age-related Macular Degeneration (AMD) through a new and innovative solution.
Create a NewCo centred around this asset and recruit a hand-selected new and experienced management team.
Significantly improve the understanding of the clinical value of the product, optimizing sales approach and in-market uptake.
Reposition the company investment case towards clinical relevance and commercial impact.
Drive data generation to broaden the areas of use, and optimise patient selection as well as practitioner targeting.
As a direct result of Treehill’s involvement, the product is today commercially available in markets around the globe improving vision in patients with AMD.
Create a NewCo centred around this asset and recruit a hand-selected new and experienced management team.
Significantly improve the understanding of the clinical value of the product, optimizing sales approach and in-market uptake.
Significantly improve the understanding of the clinical value of the product, optimizing sales approach and in-market uptake.
Significantly improve the understanding of the clinical value of the product, optimizing sales approach and in-market uptake.
Create a NewCo centred around this asset and recruit a hand-selected new and experienced management team.
Significantly improve the understanding of the clinical value of the product, optimizing sales approach and in-market uptake.
Reposition the company investment case towards clinical relevance and commercial impact.
Drive data generation to broaden the areas of use, and optimise patient selection as well as practitioner targeting.
